losartan has been researched along with Cancer of Nasopharynx in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, YT | 1 |
| Wang, HC | 1 |
| Tsai, MH | 1 |
| Su, YY | 1 |
| Yang, MY | 1 |
| Chien, CY | 1 |
1 other study available for losartan and Cancer of Nasopharynx
| Article | Year |
|---|---|
Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma.
Topics: Angiotensin Receptor Antagonists; Apoptosis; Humans; Losartan; Nasopharyngeal Carcinoma; Nasopharyng | 2021 |